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W ith a price tag of $7 billion dollars in 2011, breast reconstruction is under close scrutiny for cost reduction and value maximization in a health-
care system, experiencing increased pressure to focus on 
cost containment.1–3 Payers continue to evolve new reim-
bursement strategies to parallel geographic consolidation 
of multidisciplinary breast cancer care with bundled pay-
ments. Numerous studies have examined the costs asso-
ciated with autologous breast reconstruction.4,5 However, 
the Nationwide Inpatient Sample database shows an ab-
solute and relative increase in the number of breast re-
constructions performed with tissue expansion followed 
by exchange for a permanent implant (TE/I).6 In fact, 
TE/I reconstruction has increased more than 2-fold and 
presently accounts for the majority of all reconstructive 
breast procedures in the United States, thus highlighting 
the need for studying resource allocation and funding of 
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Background: Current cost data on tissue expansion followed by exchange for 
permanent implant (TE/I) reconstruction lack a necessary assessment of the ex-
perience of a heterogenous breast cancer patient population and their multiple 
outcome pathways. We extend our previous analysis to that of direct hospital cost 
as bundling of payments is likely to follow the changing centralization of cancer 
care at the hospital level. 
Methods: We performed a retrospective analysis (2003–2009) of TE/I reconstruc-
tions with or without an acellular dermal matrix (ADM), namely Alloderm RTM. 
Postreconstructive events were analyzed and organized into outcome pathways as 
previously described. Aggregated and normalized inpatient and outpatient hos-
pital direct costs and physician reimbursement were generated for each outcome 
pathway with or without ADM. 
Results: Three hundred sixty-seven patients were analyzed. The average 2-year hos-
pital direct cost per TE/I breast reconstruction patient was $11,862 in the +ADM 
and $12,319 in the −ADM groups (P > 0.05). Initial reconstructions were costlier in 
the +ADM ($6,868) than in the −ADM ($5,615) group, but the average cost of sub-
sequent postreconstructive events within 2 years was significantly lower in +ADM 
($5,176) than −ADM ($6,704) patients (P < 0.05). When a complication occurred, 
but reconstruction was still completed within 2 years, greater costs were incurred 
in the −ADM than in the +ADM group for most scenarios, leading to a net equaliza-
tion of cost between study groups. 
Conclusion: Although direct hospital cost is an important factor for resource and 
fund allocation, it should not remain the sole factor when deciding to use ADM 
in TE/I reconstruction. (Plast Reconstr Surg Glob Open 2016;4:e831; doi: 10.1097/
GOX.0000000000000848; Published online 9 August 2016.)
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this treatment approach.7,8 Paralleling national trends, in-
dividual institutions have reported that TE/I reconstruc-
tions account for 45% of total cost attributed to breast 
reconstruction.7 Despite these changes, there is a paucity 
of data to guide how bundling should occur for TE/I. We 
have previously reported outcome pathways in TE/I with 
acellular dermal matrices and sought to examine the costs 
incurred at the hospital level by these outcome pathways.
Practice patterns, including those for TE/I reconstruc-
tions evolve as new, innovative technology, are incorpo-
rated into practice. Acellular dermal matrices (ADMs) 
have caused a paradigm shift in TE/I reconstructions in 
the past decade, citing numerous indications, including 
but not limited to improved aesthetic outcomes, increased 
expansion volumes, and shorter time to final exchange 
for permanent implants.9–12 The cost-effectiveness of such 
technology has been examined, albeit in a limited fash-
ion, using either retrospective review of previous stud-
ies, samples of a larger cohort to extrapolate cost data, 
or only index operation costs as cost-minimization, cost-
effectiveness, and cost-utility analyses.7,13–15 To date, no 
study has performed an analysis of ADMs in two-stage im-
plant–based reconstruction using actual cost data directly 
incurred by the hospital with representation of the diver-
gent outcome pathways TE/I reconstruction patients un-
dergo. With the advent of accountable care organizations, 
bundling of payments and disbursement of funds is likely 
to occur at the hospital level. Currently, the hospital typi-
cally absorbs the cost of a device like ADM with supply cost 
of the item readily apparent to hospital managers. How-
ever, the extent to which there are off-setting cost savings 
for the hospital over time has not been well studied. It is 
imperative for plastic surgeons to be aware of the hospital 
costs associated with the services they provide patients in 
TE/I reconstruction.
Although cost data should not be the sole factor when 
developing a reconstructive plan for a patient, it should be 
examined within the context of patient demographics, risk 
factors, and their individual treatment algorithms, which 
may include chemotherapy and radiation. Current data 
about cost of TE/I reconstruction does not fully represent 
the experience of a heterogenous patient population and 
their multiple outcome pathways. Cost analyses often use 
shortened time frames, capturing only costs at or near the 
time of reconstruction and missing the full impact of ser-
vice required to complete a two-staged reconstruction. We 
extend our previous analysis to that of cost to set the stage 
for meaningful discussions between providers, patients, 
and payers to define the value of breast reconstruction.
METHODS
Study	Population
A retrospective analysis of all patients treated with 
TE/I at Barnes Jewish and Barnes Jewish West County 
Hospitals and treated by plastic surgeons from the Wash-
ington University School of Medicine from January 1, 
2003, to December 31, 2009, was conducted under the 
approval of the institutional Human Research Protection 
Office (#201106126) as previously described.16 Immedi-
ate and delayed TE/I reconstructions were included for 
analysis in patients undergoing unilateral or bilateral skin-
sparing mastectomies performed for cancer or prophy-
laxis. All TEs were textured Allergan (Allergan Medical, 
Irvine, Calif.) 133MV devices, and implants were Allergan 
round moderate- or high-profile silicone or saline devices 
(style 15, 20, 68MP, and 68HP) as these were on consign-
ment at our institution during the study period. Patients 
with concomitant or previous ipsilateral flap reconstruc-
tion, concurrent congenital or acquired ipsilateral breast 
deformity, and nipple-sparing mastectomy with immediate 
implant and patients for whom flap placement after tissue 
expansion was initially planned were excluded. Patients 
in which an ADM other than AlloDerm RTM (LifeCell, 
Branchburg, N.J.) was used were excluded because usage 
of other ADM products, including Alloderm RTU and vic-
ryl mesh, was too infrequent during the study period to 
sufficiently power a subset analysis. Medical records were 
examined for evidence of postreconstructive events, de-
fined as related procedures or complications. Complica-
tions identified included seroma, hematoma, mastectomy 
flap necrosis, wound dehiscence with loss of continuity of 
the mastectomy incision in the absence of necrosis, cel-
lulitis (infection without seroma), capsular contracture 
requiring intervention other than during the expander 
exchange, and ADM complications (poor incorporation 
or dehiscence of the scaffold). Related procedures includ-
ed unexpected explantation or capsular revisions and pro-
cedures to replace failed devices, manage complications, 
or improve symmetry. Explantation was recorded for the 
unintended removal of either the TE or permanent breast 
implant at any time during the 2-year study period. Cap-
sular revisions were documented when a major revision 
of the periprosthetic capsule performed other than at the 
implant exchange was used to obtain symmetry or favor-
able contour. Nipple areolar reconstruction was not evalu-
ated because it was often performed outside the hospital 
setting and therefore inconsistently recorded and because 
it varied according to patient preference. Common se-
quences of postreconstructive events were combined into 
outcome pathways and analyzed by study arm. Selection 
criteria for ADM use were not assessed in this study.
Cost	Analyses
Barnes Jewish Hospital provided aggregated cost data 
on selected patients, exemplifying patient scenarios or 
“cost exemplars.” For the initial reconstruction, private-
ly insured patients with no unrelated procedures were 
randomly selected in equal numbers from inpatient and 
outpatient settings to represent −ADM and +ADM recon-
structions from both earlier and later years of ADM use 
at the institution. We excluded cases with a nondominant 
brand of tissue expander or unusually long general sur-
gery portion of the case. The mix of bilateral and unilater-
al reconstructions among cost exemplars was determined 
by chi-square to be representative of the entire study arm 
for both +ADM (P > 0.05) and −ADM (P > 0.05) recon-
structions. In each study arm, a group of 3 representative 
patients was identified for each outcome pathway with 
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sufficient frequency for analysis. Patients with incomplete 
cost data or whose left and right breasts were reconstruct-
ed separately were excluded as exemplars.
The hospital supplied aggregated direct cost normal-
ized to 2011 dollars at 3% per annum for postreconstruc-
tive events of the cost exemplars in each study arm for 
each outcome pathway and for initial reconstructions. 
“Direct costs” are those that can be traced directly to a de-
partment, product, or service, excluding overhead costs, 
and thus reflect the hospital’s assessment of the cost it in-
curred, providing the specific services and supplies used 
by the patients.17 The average per-patient cost obtained 
for each group of exemplars was applied to all patients in 
the same outcome pathway and study arm. Billing opera-
tions from the Washington University Physicians medical 
group provided aggregated data on physician reimburse-
ment for these “cost exemplars” on the same basis.
Statistical	Analyses
The overall cost data between patients who had ADM 
and those who did not was amenable to statistical compari-
son with a two-sample independent t test because there 
was no variance in the averaged costs assigned to patients 
in each reconstructive pathway. Statistical analyses were 
performed using SAS/STAT version 9.2 (SAS Corpora-
tion, Cary, N.C.). Statistically significant findings were 
reported when P < 0.05. Hospital requirements preclude 
disclosure of patient-level cost data because of its propri-
etary nature. Because we could not perform patient-level 
analyses, we averaged costs for patients exemplifying a par-
ticular pathway. Because all patients in a pathway are as-
signed the same cost, based on the pathway average, there 
is no variance between patients. As such, cost differences 
between the 2 study arms for the same pathway or for the 
initial reconstruction cannot be evaluated statistically.
RESULTS
Three hundred sixty-seven of 415 patients had suf-
ficient information for inclusion in the cost analyses 
(+ADM = 265; −ADM = 102), and their demographic in-
formation is summarized in Table 1. The average age of 
patients was 50 (+ADM = 50; −ADM = 50), and body mass 
index (BMI) was 28.2 kg/m2 (+ADM = 27.7; −ADM = 29.4). 
The total average 2-year hospital direct cost per TE/I 
breast reconstruction patient was $11,862 in the +ADM 
and $12,319 in the −ADM groups (Fig. 1A). Initial recon-
structions were costlier in the +ADM ($6,868) than the 
−ADM ($5,615) group, but the average cost of subsequent 
postreconstructive events within 2 years was significantly 
lower in +ADM ($5,176) than –ADM ($6,704) patients 
(P < 0.05) (Table 2). Uneventful implant exchange cost 
an additional $2,974 in the +ADM and $4,036 in the 
–ADM groups, whereas the need for additional revisions 
further escalated cost (Table 2). Of note, only 1 patient 
in the +ADM group and none in the –ADM group experi-
enced capsular contracture requiring surgery not concur-
rent with the expander exchange.
In cases where a complication occurred, but recon-
struction was still completed within 2 years, costs incurred 
were greater in the –ADM than in +ADM group for most 
scenarios (Table 2 and Fig. 1A). Rates of cellulitis without 
seroma requiring explant with eventual implant exchange 
within 2 years (Table 2, pathway III) occurred in 4% of 
+ADM ($7,414) and 5% of –ADM ($11,298) reconstruc-
tions. Rates of seroma (Table 2, pathway IV) were also sim-
ilar in both groups (4% vs 3%) but cost more for +ADM 
($11,586) than −ADM ($8,139) reconstructions. Dehis-
cence without necrosis (Table 2, pathway V) was more 
common in −ADM versus +ADM reconstructions (12% vs 
4%) with an additional cost of $12,009 and $14,200, re-
spectively. Necrosis without dehiscence (Table 2, pathway 
VI) occurred more commonly with ADM reconstruction 
(6% vs 2%) but cost less on average per patient ($6,398 vs 
$8,762). Rates of conversion to autologous reconstruction 
(Table 2, pathway VII) were similar in both groups and 
cost $14,434 and $19,169 for +ADM and −ADM groups. 
Cellulitis eventually leading to explantation with an aban-
doned reconstruction at 2 years (Table 2, pathway VIII) 
was less costly in the +ADM group ($2,224 vs $5,004). 
Reconstruction that was incomplete or abandoned after 
complications (Table 2, pathway IX) were similar (7% 
and 5%) with costs of $3,758 and $2,648 in the +ADM and 
−ADM groups.
Surgeon charges and reimbursements with ADM for 
inpatient services were $5,900 and $3,887 and for outpa-
tient services $5,103 and $3,849, respectively (Fig. 1B). 
Without ADM, surgeon charges and reimbursements for 
inpatient services were $7,116 and $3,028 and for outpa-
tient services $3,559 and $3,144, respectively. Charges and 
reimbursements were not significantly different regardless 
of ADM use or inpatient versus outpatient setting of ser-
vices rendered.
The average surgeon charges per patient for postre-
construction services was $10,112 with ADM and $12,476 
without ADM. Average surgeon reimbursement per pa-
tient for postreconstruction services was $4,067 with ADM 
and $4,887 without ADM. Physician charges and reim-
bursements were similar between study arms (Fig. 1C).
DISCUSSION
With the advent of bundled payments and geographic 
consolidation of cancer care around hospitals and cancer 
centers,18,19 it remains imperative for plastic surgeons to be 
informed about the costs at the hospital level for patients 
who undergo TE/I reconstruction, as this is the most 
commonly performed reconstruction and is increasing 
in popularity.6 Previous studies have compared the costs 
of TE/I reconstruction versus autologous reconstruction, 
but the TE/I reconstructions examined did not include 
Table 1. Cost Study Patient Population Demographics
+ADM −ADM
No. of patients 265 102
Age (y), mean (SD) 50 (9.8) 50 (9.3)
BMI, kg/m2, mean (SD) 28 (6.6) 30 (8.2)
Bilateral, n (%) 126 (48) 45 (44)
Radiation, n (%) 64 (24) 36 (35)
Smoker, n (%) 36 (14) 16 (16)
BMI, body mass index.
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reconstructions with ADM.5,8 Other studies examining the 
cost of ADM use have studied the costs incurred based on 
individual complication events and not in the setting of a 
longitudinal experience or outcome pathways as we have 
previously described.13–16 The present study is important 
because very little has been published previously about 
cost from a hospital’s perspective as these data are diffi-
cult to obtain, yet it is the hospital that absorbs the cost of 
the ADM. Although the cost of ADM or any surgical de-
vice may be obvious to the hospital, no hospital adminis-
tration’s budget has a line item that would show offsetting 
cost reductions over time. We think that the perspective 
offered by this study is not only novel but also particularly 
informative to discussions on value in breast reconstruc-
tion.
At our institution, the use of ADM in TE/I reconstruc-
tion increased substantially after its introduction in 2005, 
was limited to sheets that were 12 × 6, 16 × 6, or 16 × 8 cm2 
and parallels other single-institution experiences with 
ADM.7,15 One of the main criticisms of using any ADM is its 
product cost. In our series, the initial direct hospital cost 
of TE/I reconstruction was higher when ADM was used, 
but the difference was lower than the list price for even the 
smallest sheet of ADM used in this series (6 × 12 cm).13,20 
One variable that may influence this cost discrepancy is 
lower negotiated ADM product costs at the institutional 
level. Our analysis, however, highlights an important fact 
about not only the present study but also cost analysis as a 
whole: the cost of an ADM may not be accurately reflected 
by simply inputting its retail cost into a hypothetical model 
as its utilization may impact operative time, surgical tech-
nique, negotiated product costs with the vendor, among 
other factors that influence direct hospital cost.
Cost also needs to be evaluated in the context of pa-
tient’s outcome pathways. We found that the weighted, 
average hospital direct cost of reconstructive events in 
Fig. 1. two-year hospital direct costs, surgeon charges, and reimbursement for staged te/i reconstructions. Data are reported as per-
patient average. a, Hospital direct costs, including initial te operation ±aDM and 2 y post te reconstructive events. B, Surgeon charges 
and reimbursements for initial te/i reconstruction ±aDM in inpatient versus outpatient settings. c, Surgeon charges and reimbursements 
for 2 y after initial te reconstruction ±aDM. iP, inpatient setting; OP, outpatient setting.





Initial TE reconstruction $6,686 $5,615
Outcome	pathway	after	initial	TE	reconstruction Average	hospital	direct	cost	per	patient	for		
postreconstructive	services,	in	2011	$
  I. Uneventful two-stage expander reconstruction within 2 y $2,974 $4,036
  II. Successful two-stage expander reconstruction with additional services
   IIa. + extra procedure for symmetry $4,792 $6,112
   IIb. + extra procedure for other reasons $8,838 $7,454
   IIc. + ADM complication $5,755
   IId. + extra capsule revision for capsular contracture $8,003
  III. Cellulitis without seroma, eventual explant, and stage 2 completed $7,414 $11,298
  IV. Seroma, stage II completed $11,586 $8,139
  V. Dehiscence with or without necrosis, no seroma, stage 2 completed $14,200 $12,009
  VI. Necrosis without dehiscence, no seroma, stage 2 completed $6,398 $8,762
  VII. Converted to autologous reconstruction $14,434 $19,169
  VIII. Cellulitis, eventual explant, reconstruction abandoned $2,224 $5,004
  IX. Reconstruction incomplete or abandoned after complications 
(seroma, necrosis, and dehiscence)
$3,758 $2,648
Postreconstructive events within 2 y $5,176 $6,704 0.0003
Grand total: initial reconstruction + postreconstructive events $11,862 $12,319 0.2788
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the 2 years after TE insertion varied by clinical pathway, 
but overall it was significantly lower in patients who had 
ADM. The net effect was an equalization of overall cost 
between study arms inclusive of the initial TE procedure 
and any procedures up until exchange with an implant or 
autologous flap within the 2-year period of the study. Im-
portantly, although the majority of 2-year reconstructive 
pathways were less costly in the +ADM study arm, these 
differences must be interpreted with caution as pathway-
level statistical comparisons could not be performed for 
reasons outlined in the Methods section.
The 2-year costs of successful reconstructions that 
require no or only minor revisions or unsuccessful re-
constructions that were abandoned were considerably 
cheaper than those requiring interventions for salvage. 
BMI, radiation, and smoking influenced postreconstruc-
tive events and the outcome pathways that they associate 
with to a greater extent than whether ADM was used as 
we have previously reported.16 Hence, the decision to use 
ADM or not needs to be based on patient-specific factors, 
including but not limited to BMI and radiation and not 
solely on cost.
We found that the percent of patients who were irradi-
ated differed significantly between the study arms (±ADM, 
P < 0.05). Our previous study found that irradiated patients 
were 2.2 times more likely than patients without radiation 
to have complications or additional procedures, veering 
away from an uneventful reconstruction.16 Subset analy-
sis of ADM patients who were irradiated showed average 
downstream costs of $6,422 versus $4,704 for those with-
out radiation. If 35% of the ADM study arm had incurred 
$1,719 in additional costs (i.e., 92 instead of 64 irradiated 
patients), we estimate this would had added $181.59 to 
total cost per ADM patient. This modest increase in cost 
(1.5%) is not enough to change our overall finding that 
over 2 years, average cost per patient reconstructed with 
ADM trended lower albeit not significantly than patients 
without ADM. Our findings add to previous reports of 
TE/I reconstruction without ADM in which pre- or post-
operative radiation did not significantly affect costs.8
Our analysis included surgeon charges and reimburse-
ments for initial TE/I reconstruction ±ADM in inpatient 
versus outpatient settings and also surgeon charges and 
reimbursements for 2 years after initial TE reconstruction 
±ADM. These were not found to be significantly different, 
suggesting that physician provider cost does not vary with 
the use of ADM at our institution. Although charges and 
reimbursements are measures of revenue rather than phy-
sician cost, the findings suggest that revenue incentives 
for physicians are not misaligned with cost incentive for 
hospitals, as often can happen. From the perspectives we 
analyzed, over a 2-year time period, neither hospitals nor 
physicians have a significant financial incentive to use or 
avoid the use of ADM.
Our study has several limitations. Analysis was based 
on “direct costs” or the cost that can be traced directly 
to a department, product, or service, excluding overhead 
costs.17 We felt that the hospital’s assessment of the cost it 
incurred providing the specific services and supplies used 
by the patients would be valuable information with the 
advent of systems, such as accountable care organizations 
and reimbursement based on hospital billing. In addition, 
although our assessment of direct cost is at 2 hospitals, it 
still represents the experience of 1 hospital system but lays 
the foundation for studies in other institutions in other 
geographic locations. In our study, costs were aggregated 
from a limited group of patients, and line item and pa-
tient-level cost detail were unavailable.
Trends in TE/I reconstruction are rapidly evolving 
with increased use of fat grafting as a subsequent pro-
cedure.20 Further investigation on the costs incurred by 
these procedures will need to be examined as fat graft-
ing is becoming a near routine “touch up” procedure for 
breast revisions in TE/I reconstructions at many institu-
tions, including our own.
Because there is an equalization of overall direct hos-
pital cost between the 2 study groups, our findings point 
to ADM use as 1 factor in a complex web of interactions 
that impact costs. Its limited impact on cost over a 2-year 
period suggests that the more important focus might be 
on careful attention to risk and patient factors associated 
with different TE/I reconstruction outcome pathways.
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